Makoto Nishio

Makoto Nishio

UNVERIFIED PROFILE

Are you Makoto Nishio?   Register this Author

Register author
Makoto Nishio

Makoto Nishio

Publications by authors named "Makoto Nishio"

Are you Makoto Nishio?   Register this Author

100Publications

3208Reads

48Profile Views

Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.

Int J Clin Oncol 2020 Jan 10;25(1):67-73. Epub 2019 Sep 10.

Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto, Tokyo, 1358550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01537-4DOI Listing
January 2020

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Thorac Cancer 2020 Jan 13. Epub 2020 Jan 13.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13299DOI Listing
January 2020

Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.

J Thorac Oncol 2020 Jan 21. Epub 2020 Jan 21.

Division of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa, Japan; Nano Life Science Institute, Kanazawa University, Kanazawa University, Kanazawa, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.01.001DOI Listing
January 2020

Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules.

Clin Lung Cancer 2020 Jan 30. Epub 2020 Jan 30.

Department of Thoracic Surgical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.01.015DOI Listing
January 2020

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Lung Cancer 2019 07 27;133:4-9. Epub 2019 Apr 27.

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.04.022DOI Listing
July 2019

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Intern Med 2019 15;58(10):1479-1484. Epub 2019 May 15.

Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.1673-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548921PMC
June 2019

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Eur J Cancer 2019 May 13;113:78-86. Epub 2019 Apr 13.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.012DOI Listing
May 2019

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.

Clin Lung Cancer 2018 09 10;19(5):435-440.e1. Epub 2018 May 10.

Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.04.006DOI Listing
September 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.

J Thorac Oncol 2018 07 24;13(7):915-925. Epub 2018 Apr 24.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.005DOI Listing
July 2018

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Lung Cancer 2018 07 17;121:37-40. Epub 2018 Apr 17.

Thoracic Center, St. Luke's International Hospital, Chuo-ku, Tokyo 104-8560 Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.04.015DOI Listing
July 2018

Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.

Support Care Cancer 2018 May 24;26(5):1505-1513. Epub 2017 Nov 24.

Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3974-3DOI Listing
May 2018

[Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].

Gan To Kagaku Ryoho 2018 Feb;45(2):257-264

Dept. of Thoracic Oncology, Hyogo Cancer Center.

View Article

Download full-text PDF

Source
February 2018

Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Jpn J Clin Oncol 2017 Dec;47(12):1189-1192

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyx133DOI Listing
December 2017

Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.

Cancer Med 2017 Oct 18;6(10):2347-2356. Epub 2017 Sep 18.

Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633594PMC
October 2017

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.

Clin Lung Cancer 2017 09 22;18(5):527-534.e1. Epub 2016 Dec 22.

Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.12.002DOI Listing
September 2017

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.

Anticancer Res 2017 08;37(8):4229-4232

Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11814DOI Listing
August 2017

Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation.

Sci Rep 2017 06 22;7(1):4059. Epub 2017 Jun 22.

Division of Experimental Chemotherapy, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-04324-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481446PMC
June 2017

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

J Clin Oncol 2017 May 15;35(14):1515-1521. Epub 2017 Mar 15.

Tomohide Tamura, St Luke's International Hospital; Yuichiro Ohe, National Cancer Center Hospital; Hiroshi Kuriki, Tadashi Shimada, and Tomohiro Tanaka, Chugai Pharmaceutical; Kengo Takeuchi, Japanese Foundation for Cancer Research; Makoto Nishio, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo; Katsuyuki Kiura, Okayama University Hospital, Okayama; Takashi Seto, National Kyusyu Cancer Center, Fukuoka; Kazuhiko Nakagawa, Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; Toyoaki Hida, Aichi Cancer Center, Nagoya; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Masao Harada, Hokkaido Cancer Center, Sapporo; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; and Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.5749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704PMC
May 2017

Development of indication criteria for preoperative examination in lung cancer.

Asian Cardiovasc Thorac Ann 2017 May 11;25(4):281-286. Epub 2017 May 11.

1 Department of Thoracic Surgical Oncology, The Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0218492317709698DOI Listing
May 2017

A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis.

Sci Rep 2017 02 8;7:42186. Epub 2017 Feb 8.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/srep42186
Publisher Site
http://dx.doi.org/10.1038/srep42186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297242PMC
February 2017

High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.

Pathol Int 2017 Jan 15;67(1):37-44. Epub 2016 Dec 15.

Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12489DOI Listing
January 2017

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Significant prognostic factors for completely resected pN2 non-small cell lung cancer without neoadjuvant therapy.

Ann Thorac Cardiovasc Surg 2015 16;21(4):345-53. Epub 2015 Feb 16.

Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5761/atcs.oa.14-00262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904870PMC
June 2016

Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma.

Cancer Sci 2016 Mar 19;107(3):320-5. Epub 2016 Feb 19.

Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814245PMC
March 2016

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Lung Cancer 2016 Mar 30;93:43-6. Epub 2015 Dec 30.

Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ward, Tokyo 135-8550, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.12.011DOI Listing
March 2016

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1.

Medicine (Baltimore) 2015 Dec;94(51):e2324

From the Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR) (EM, NM, HO, HN, YI); Thoracic Center, The Cancer Institute Hospital, JFCR, Tokyo (FO, MN, SO); and Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (EM, MI).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000002324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697988PMC
December 2015

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.

Cancer Sci 2015 Nov 7;106(11):1554-60. Epub 2015 Oct 7.

Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714693PMC
November 2015

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.

J Thorac Oncol 2015 Jul;10(7):1058-66

*The Cancer Institute Hospital of JFCR, Tokyo, Japan; †Shizuoka Cancer Center, Shizuoka, Japan; ‡National Kyushu Cancer Center, Fukuoka, Japan; §Novartis Pharma K.K., Tokyo, Japan; ¶Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and ‖Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467585PMC
July 2015

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Invest New Drugs 2015 Jun 18;33(3):632-40. Epub 2015 Mar 18.

Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0227-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0227-5DOI Listing
June 2015

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.

Lung Cancer 2015 Jun 19;88(3):275-81. Epub 2015 Mar 19.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.03.010DOI Listing
June 2015